Advertisement

Picture [iito] No Tracking 650x80px
Document › Details

Immunic, Inc.. (8/2/20). "Press Release: Immunic, Inc. Reports Positive Top-line Data from Phase 2 EMPhASIS Trial of IMU-838 in Patients with Relapsing-Remitting Multiple Sclerosis – Reports Results 2020 Q2". New York, NY.

Organisation Organisation Immunic Inc. (Nasdaq: IMUX)
  Group Immunic (Group)
Products Product IMU-838 (Immunic)
  Product 2 phase 2 study
Persons Person Mühler, Andreas (Immunic 201604– CMO + Co-Founder)
  Person 2 Vitt, Daniel (Immunic 201701– CEO before 4SC 1997–201612 CSO + Co-Founder before Univ Würzburg)
     


   
Record changed: 2020-09-04

Advertisement

Picture Kentro Design Corporate and Web Design Berlin 650x65px

More documents for Immunic (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture [iito] Made Without Love 650x80px




» top